company background image
RVLP

RVL Pharmaceuticals NasdaqGS:RVLP Stock Report

Last Price

US$1.47

Market Cap

US$145.8m

7D

-2.6%

1Y

3.5%

Updated

27 Nov, 2022

Data

Company Financials +
RVLP fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RVLP Stock Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.

RVL Pharmaceuticals plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for RVL Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.47
52 Week HighUS$2.99
52 Week LowUS$0.98
Beta1.07
1 Month Change-18.33%
3 Month Change-31.31%
1 Year Change3.52%
3 Year Change-78.01%
5 Year Changen/a
Change since IPO-81.96%

Recent News & Updates

Recent updates

RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

Jul 04
RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt

New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Apr 01
New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)

Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

Aug 20
Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt Extensively

May 05
These 4 Measures Indicate That Osmotica Pharmaceuticals (NASDAQ:OSMT) Is Using Debt Extensively

An Intrinsic Calculation For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Suggests It's 33% Undervalued

Mar 24
An Intrinsic Calculation For Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Suggests It's 33% Undervalued

Osmotica Pharmaceuticals'(NASDAQ:OSMT) Share Price Is Down 35% Over The Past Year.

Mar 01
Osmotica Pharmaceuticals'(NASDAQ:OSMT) Share Price Is Down 35% Over The Past Year.

Are Institutions Heavily Invested In Osmotica Pharmaceuticals plc's (NASDAQ:OSMT) Shares?

Feb 01
Are Institutions Heavily Invested In Osmotica Pharmaceuticals plc's (NASDAQ:OSMT) Shares?

Osmotica Pharmaceuticals plc (NASDAQ:OSMT): Is Breakeven Near?

Jan 04
Osmotica Pharmaceuticals plc (NASDAQ:OSMT): Is Breakeven Near?

Here's Why Osmotica Pharmaceuticals (NASDAQ:OSMT) Can Manage Its Debt Responsibly

Dec 09
Here's Why Osmotica Pharmaceuticals (NASDAQ:OSMT) Can Manage Its Debt Responsibly

Shareholder Returns

RVLPUS PharmaceuticalsUS Market
7D-2.6%1.6%1.3%
1Y3.5%9.9%-18.5%

Return vs Industry: RVLP underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: RVLP exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is RVLP's price volatile compared to industry and market?
RVLP volatility
RVLP Average Weekly Movement11.0%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: RVLP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: RVLP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a156Brian Markisonhttps://www.rvlpharma.com

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.

RVL Pharmaceuticals plc Fundamentals Summary

How do RVL Pharmaceuticals's earnings and revenue compare to its market cap?
RVLP fundamental statistics
Market CapUS$145.76m
Earnings (TTM)-US$53.05m
Revenue (TTM)US$42.77m

3.4x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RVLP income statement (TTM)
RevenueUS$42.77m
Cost of RevenueUS$7.98m
Gross ProfitUS$34.80m
Other ExpensesUS$87.84m
Earnings-US$53.05m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin81.35%
Net Profit Margin-124.02%
Debt/Equity Ratio81.6%

How did RVLP perform over the long term?

See historical performance and comparison